TWI890796B - 用於治療或預防Th2介導性疾病之含PD-1激動劑之醫藥組合物 - Google Patents

用於治療或預防Th2介導性疾病之含PD-1激動劑之醫藥組合物

Info

Publication number
TWI890796B
TWI890796B TW110118921A TW110118921A TWI890796B TW I890796 B TWI890796 B TW I890796B TW 110118921 A TW110118921 A TW 110118921A TW 110118921 A TW110118921 A TW 110118921A TW I890796 B TWI890796 B TW I890796B
Authority
TW
Taiwan
Prior art keywords
cells
human
antibodies
antibody
agonist
Prior art date
Application number
TW110118921A
Other languages
English (en)
Chinese (zh)
Other versions
TW202210099A (zh
Inventor
本庶佑
太田明夫
但馬正樹
鎌田春彦
永田諭志
鈴木健介
大城裕也
徳丸陽介
Original Assignee
公益財團法人神戸醫療産業都市推進機構
國立研究開發法人醫藥基盤 健康 營養研究所
日商明治制果藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公益財團法人神戸醫療産業都市推進機構, 國立研究開發法人醫藥基盤 健康 營養研究所, 日商明治制果藥業股份有限公司 filed Critical 公益財團法人神戸醫療産業都市推進機構
Publication of TW202210099A publication Critical patent/TW202210099A/zh
Application granted granted Critical
Publication of TWI890796B publication Critical patent/TWI890796B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW110118921A 2020-05-25 2021-05-25 用於治療或預防Th2介導性疾病之含PD-1激動劑之醫藥組合物 TWI890796B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020090526 2020-05-25
JP2020-090526 2020-05-25

Publications (2)

Publication Number Publication Date
TW202210099A TW202210099A (zh) 2022-03-16
TWI890796B true TWI890796B (zh) 2025-07-21

Family

ID=78744780

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110118921A TWI890796B (zh) 2020-05-25 2021-05-25 用於治療或預防Th2介導性疾病之含PD-1激動劑之醫藥組合物

Country Status (7)

Country Link
US (1) US20230183347A1 (https=)
EP (1) EP4159235A4 (https=)
JP (1) JP7754455B2 (https=)
KR (1) KR20230015348A (https=)
CN (1) CN115697405A (https=)
TW (1) TWI890796B (https=)
WO (1) WO2021241523A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
KR20240137086A (ko) * 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168745A1 (en) * 2018-03-02 2019-09-06 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN107149530A (zh) * 2016-03-04 2017-09-12 吴东 一种洗头装置
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
CN107149680A (zh) 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
CN106924718A (zh) 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168745A1 (en) * 2018-03-02 2019-09-06 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Nemeth, Zoltan H et al. Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus vol. 9,4 2017/04/19 e1177
期刊 Song, Mi-Young et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis Gut vol. 64,2 (2015): 260-71..Gut.2015. /02/01;期刊 Nemeth, Zoltan H et al. Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus vol. 9,4 2017/04/19 e1177 *

Also Published As

Publication number Publication date
US20230183347A1 (en) 2023-06-15
TW202210099A (zh) 2022-03-16
CN115697405A (zh) 2023-02-03
EP4159235A1 (en) 2023-04-05
KR20230015348A (ko) 2023-01-31
EP4159235A4 (en) 2024-07-10
JPWO2021241523A1 (https=) 2021-12-02
JP7754455B2 (ja) 2025-10-15
WO2021241523A1 (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
RU2203682C2 (ru) Фармацевтическая композиция для лечения иммунных заболеваний
US8389016B2 (en) Use of a CD28 binding substance for making a pharmaceutical composition
TWI890796B (zh) 用於治療或預防Th2介導性疾病之含PD-1激動劑之醫藥組合物
CN106939049B (zh) 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
CN116425876A (zh) Bcma结合分子及其使用方法
JP2018522907A (ja) Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞
JP2018515123A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CN112955469B (zh) 新型拮抗性抗tnfr2抗体分子
WO2002076504A1 (en) Remedies for inflammatory bowel diseases
WO2014124217A1 (en) A selective high-affinity immune stimulatory reagent and uses thereof
CN116162168A (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
CN117693528A (zh) 抗cll1抗体及其构建体
JP2024522095A (ja) 抗体
Soulillou et al. Monoclonal anti‐IL2‐receptor in organ transplantation
US20240350630A1 (en) Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
TW202540189A (zh) 在組合療法中能夠結合ｏｘ４０之抗體
TW202607042A (zh) 多特異性抗原結合蛋白
EP4714981A1 (en) Immune effector cell and use thereof
EP3868402A1 (en) Maturation suppressor and maturation suppression method for dendritic cells, and pharmaceutical composition
Paluch Manipulating immune checkpoint signalling pathways with antibodies
HK40108858A (zh) 抗cll1抗体及其构建体
WO2024140836A1 (zh) 靶向nkg2d配体的融合蛋白与嵌合抗原受体细胞的组合及其用途
AU2003262479B2 (en) A Pharmaceutical Composition for Treating Immune Diseases
HK40107296A (zh) 抗体
Swana Generation and chracterisation of anti-LILR antibodies for immunotherapy